Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases
- Supplementary File 1:
PDF-Document (PDF, 828 KiB)
Chauvierre, C.; Aid-Launais, R.; Aerts, J.; Chaubet, F.; Maire, M.; Chollet, L.; Rolland, L.; Bonafé, R.; Rossi, S.; Bussi, S.; Cabella, C.; Dézsi, L.; Fülöp, T.; Szebeni, J.; Chahid, Y.; Zheng, K.H.; Stroes, E.S.G.; Le Guludec, D.; Rouzet, F.; Letourneur, D. Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. Mar. Drugs 2019, 17, 699. https://doi.org/10.3390/md17120699
Chauvierre C, Aid-Launais R, Aerts J, Chaubet F, Maire M, Chollet L, Rolland L, Bonafé R, Rossi S, Bussi S, Cabella C, Dézsi L, Fülöp T, Szebeni J, Chahid Y, Zheng KH, Stroes ESG, Le Guludec D, Rouzet F, Letourneur D. Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. Marine Drugs. 2019; 17(12):699. https://doi.org/10.3390/md17120699
Chicago/Turabian StyleChauvierre, Cédric, Rachida Aid-Launais, Joël Aerts, Frédéric Chaubet, Murielle Maire, Lucas Chollet, Lydia Rolland, Roberta Bonafé, Silvia Rossi, Simona Bussi, Claudia Cabella, Laszlo Dézsi, Tamas Fülöp, Janos Szebeni, Youssef Chahid, Kang H. Zheng, Erik S. G. Stroes, Dominique Le Guludec, François Rouzet, and Didier Letourneur. 2019. "Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases" Marine Drugs 17, no. 12: 699. https://doi.org/10.3390/md17120699